<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Braga A</submitter><funding>European Research Council</funding><funding>Wings for Life</funding><funding>International Foundation for Research in Paraplegia</funding><pagination>2677-2690</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7704756</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>28(12)</volume><pubmed_abstract>Spinal cord injury (SCI) is a debilitating neurological condition characterized by different cellular and molecular mechanisms that interplay in exacerbating the progression of the pathology. No fully restorative therapies are yet available, and it is thus becoming recognized that combinatorial approaches aimed at addressing different aspects of SCI will likely results in greater functional outcomes. Here we employed packaging RNA-mediated RNA interference (pRNA-RNAi) nanotherapeutics to downregulate in situ the expression of lipocalin 2 (Lcn2), a known mediator of neuroinflammation and autocrine mediator of reactive astrogliosis, and to create a more amenable niche for the subsequent transplantation of induced neural stem cells (iNSCs). To our knowledge, this is the first approach that ta</pubmed_abstract><journal>Molecular therapy : the journal of the American Society of Gene Therapy</journal><pubmed_title>Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice.</pubmed_title><pmcid>PMC7704756</pmcid><funding_grant_id>260511</funding_grant_id><pubmed_authors>Rutigliani C</pubmed_authors><pubmed_authors>Braga A</pubmed_authors><pubmed_authors>Verheyen J</pubmed_authors><pubmed_authors>Pluchino S</pubmed_authors><pubmed_authors>Hamel R</pubmed_authors><pubmed_authors>Bandiera S</pubmed_authors><pubmed_authors>Smith JA</pubmed_authors><pubmed_authors>Edenhofer F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice.</name><description>Spinal cord injury (SCI) is a debilitating neurological condition characterized by different cellular and molecular mechanisms that interplay in exacerbating the progression of the pathology. No fully restorative therapies are yet available, and it is thus becoming recognized that combinatorial approaches aimed at addressing different aspects of SCI will likely results in greater functional outcomes. Here we employed packaging RNA-mediated RNA interference (pRNA-RNAi) nanotherapeutics to downregulate in situ the expression of lipocalin 2 (Lcn2), a known mediator of neuroinflammation and autocrine mediator of reactive astrogliosis, and to create a more amenable niche for the subsequent transplantation of induced neural stem cells (iNSCs). To our knowledge, this is the first approach that ta</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-04-20T03:42:13.895Z</modification><creation>2022-02-11T13:25:30.546Z</creation></dates><accession>S-EPMC7704756</accession><cross_references><pubmed>32877696</pubmed><doi>10.1016/j.ymthe.2020.08.001</doi></cross_references></HashMap>